Table 4.

Multivariate analysis of risk factors associated with t-MDS/t-AML (case-control study)

Risk Factors All Cases (n = 22) RR (95% CI)4-150-5/5q- or -7/7q(n = 10) RR (95% CI)4-15011q23/21q22 (n = 6) RR (95% CI)4-150
Alkylating agent score  
 <170  1.0  1.0  1.0  
 >170 1.2 (0.4-3.4)  1.5 (0.4-5.4)  1.1 (0.2-5.1) 
 non-VP-16 primed group4-151 1.4 (0.4-4.2)  1.3 (0.3-4.7) 2.8 (0.3-29.9)  
Topoisomerase score  
 <110  1.0 1.0  1.0  
 >110  1.0 (0.4-2.8)  0.8 (0.2-2.8) 1.4 (0.3-6.5)  
 non-VP-16 primed group4-151 1.0 (0.3-3.0) 0.7 (0.2-2.7)  2.3 (0.2-24.1)  
Pretransplant radiation 
 No  1.0  1.0  1.0  
 Yes  2.5 (0.9-7.3) 2.4 (0.7-9.0)  2.3 (0.5-10.9)  
 non-VP-16 primed group4-151 3.2 (1.0-10.2)‡ 2.5 (0.7-9.3)  7.1 (0.7-76)  
Source of stem cells  
 BM  1.0  1.0  1.0 
 BM + PSC/PSC  0.9 (0.2-3.5)  0.6 (0.1-2.9) 0.5 (0.1-3.3)  
 non-VP-16 primed group4-151 0.8 (0.2-3.0) 0.7 (0.1-3.2)  0.2 (0.0-1.7)  
Priming with VP-16 
 No  1.0  1.0  1.0  
 Yes  2.9 (0.6-14.3) NC  12.3 (2.0-76)‡ 
Conditioning regimens 
 Cytoxan  
  No  1.0  1.0  1.0  
  Yes 0.5 (0.3-0.9)  0.3 (0.2-0.6)  0.2 (0.1-0.4) 
 non-VP-16 primed group4-151 0.5 (0.3-0.8)  0.3 (0.2-0.6) 0.1 (0.0-0.3)  
 VP-16  
  No  1.0  1.0  1.0 
  Yes  0.5 (0.3-0.9)  0.3 (0.2-0.6)  0.2 (0.1-0.4) 
 non-VP-16 primed group4-151 0.5 (0.3-0.8)  0.3 (0.2-0.6) 0.1 (0.0-0.3)  
 BCNU  
  No  1.0  1.0  1.0 
  Yes  0.7 (0.2-2.1)  1.0 (0.3-3.8)  0.6 (0.1-3.1) 
 non-VP-16 primed group4-151 0.7 (0.2-2.3)  1.0 (0.2-3.8) 0.6 (0.1-5.8)  
 TBI  
  No  1.0  1.0  1.0 
  Yes  1.5 (0.5-4.6)  1.0 (0.3-4.1)  1.8 (0.3-10.1) 
 non-VP-16 primed group4-151 1.5 (0.4-5.0)  1.0 (0.3-4.1) 1.8 (0.2-19.3) 
Risk Factors All Cases (n = 22) RR (95% CI)4-150-5/5q- or -7/7q(n = 10) RR (95% CI)4-15011q23/21q22 (n = 6) RR (95% CI)4-150
Alkylating agent score  
 <170  1.0  1.0  1.0  
 >170 1.2 (0.4-3.4)  1.5 (0.4-5.4)  1.1 (0.2-5.1) 
 non-VP-16 primed group4-151 1.4 (0.4-4.2)  1.3 (0.3-4.7) 2.8 (0.3-29.9)  
Topoisomerase score  
 <110  1.0 1.0  1.0  
 >110  1.0 (0.4-2.8)  0.8 (0.2-2.8) 1.4 (0.3-6.5)  
 non-VP-16 primed group4-151 1.0 (0.3-3.0) 0.7 (0.2-2.7)  2.3 (0.2-24.1)  
Pretransplant radiation 
 No  1.0  1.0  1.0  
 Yes  2.5 (0.9-7.3) 2.4 (0.7-9.0)  2.3 (0.5-10.9)  
 non-VP-16 primed group4-151 3.2 (1.0-10.2)‡ 2.5 (0.7-9.3)  7.1 (0.7-76)  
Source of stem cells  
 BM  1.0  1.0  1.0 
 BM + PSC/PSC  0.9 (0.2-3.5)  0.6 (0.1-2.9) 0.5 (0.1-3.3)  
 non-VP-16 primed group4-151 0.8 (0.2-3.0) 0.7 (0.1-3.2)  0.2 (0.0-1.7)  
Priming with VP-16 
 No  1.0  1.0  1.0  
 Yes  2.9 (0.6-14.3) NC  12.3 (2.0-76)‡ 
Conditioning regimens 
 Cytoxan  
  No  1.0  1.0  1.0  
  Yes 0.5 (0.3-0.9)  0.3 (0.2-0.6)  0.2 (0.1-0.4) 
 non-VP-16 primed group4-151 0.5 (0.3-0.8)  0.3 (0.2-0.6) 0.1 (0.0-0.3)  
 VP-16  
  No  1.0  1.0  1.0 
  Yes  0.5 (0.3-0.9)  0.3 (0.2-0.6)  0.2 (0.1-0.4) 
 non-VP-16 primed group4-151 0.5 (0.3-0.8)  0.3 (0.2-0.6) 0.1 (0.0-0.3)  
 BCNU  
  No  1.0  1.0  1.0 
  Yes  0.7 (0.2-2.1)  1.0 (0.3-3.8)  0.6 (0.1-3.1) 
 non-VP-16 primed group4-151 0.7 (0.2-2.3)  1.0 (0.2-3.8) 0.6 (0.1-5.8)  
 TBI  
  No  1.0  1.0  1.0 
  Yes  1.5 (0.5-4.6)  1.0 (0.3-4.1)  1.8 (0.3-10.1) 
 non-VP-16 primed group4-151 1.5 (0.4-5.0)  1.0 (0.3-4.1) 1.8 (0.2-19.3) 
F4-150

95% confidence interval.

F4-151

Non-VP-16 primed group denotes patients who did not receive priming with VP-16 prior to stem cell collection.

‡

P ≤ 0.05.

NC indicates not convergent.

View Large